Know Cancer

forgot password

124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study

3 Years
Not Enrolling

Thank you

Trial Information

124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study

Accurate radiation dose evaluation is important in patients with malignant tumors, and this
is especially critical in children with NB who will be receiving several dose of therapeutic
131I. The accurate quantification of the isotope-labeled analog can only be achieved by
using positron emission compounds, such as 124I. Unlike planar images, which were used to
obtain kinetic information, and SPECT reconstruction modalities that were aimed to assess
the spatial distribution of radioactivity, 3D PET imaging-based dosimetry is a method which
provides a more accurate estimation of the cumulated radioactivity distribution. Because PET
provides better quantitative accuracy, when compared to SPECT regarding the tissue absorbed
information, we hypothesize PET would better correspond with tumor response and normal organ
toxicity. Early studies using I-124 for dosimetry in thyroid cancer have been promising.

Demonstration of the feasibility and accuracy of this new imaging modality, with the
excellent prospect for more accurate dosimetry, will improve tumor localization and optimize
therapeutic dosing with 131I-MIBG. The results of our work may potentially have also
implications in the study of other neuroendocrine tumors. The Section of Nuclear Medicine
and the Laboratory of Functional Imaging at the University of California, San Francisco, are
equipped with state of the art instruments and is run by a highly skilled staff which will
guarantee the success of the proposed research.

Inclusion Criteria:

- Age: Patients must be >/= 3 years of age and able to cooperate for the PET CT scan
when registered on study.

- Diagnosis: Patients must have a diagnosis of neuroblastoma either by histologic
verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow
with increased urinary catecholamine metabolites.

- Disease Status: Patients must have high-risk neuroblastoma with at least ONE of the

- Recurrent/progressive disease at any time. Biopsy is not required, even if there is a
partial response to intervening therapy.

- Refractory disease (i.e. less than a partial response to frontline therapy, including
a minimum of 4 cycles of chemotherapy). No biopsy is required for eligibility for
this study.

- 123I-MIBG Uptake: Patients must have MIBG evaluable disease which is defined as
evidence of uptake into tumor at >/= one site within 4 weeks prior to entry on study
and subsequent to any intervening therapy.

- 131I-MIBG Therapy: Patients must meet eligibility criteria for 131I-MIBG therapy.

- Reproductive Function: All post-menarchal females must have a negative beta-HCG
within 2 weeks prior to receiving the dose of 124I-MIBG. Males and females of
childbearing potential must practice an effective method of birth control while
participating on this study, to avoid possible damage to the fetus.

Exclusion Criteria:

- Pregnancy or lactating with the intent of breast feeding.

- Patients who require general anesthesia for MIBG imaging studies.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

Measurements of organ dosimetry using high specific activity (no carrier added) 124I-MIBG PET/CT in patients with refractory or relapsed neuroblastoma

Outcome Time Frame:

Participants will have PET/CT scans on Days 0 - week 7. Average study participation is approximately 7 weeks.

Safety Issue:


Principal Investigator

Katherine Matthay, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of California, San Francisco


United States: Food and Drug Administration

Study ID:




Start Date:

June 2012

Completion Date:

December 2016

Related Keywords:

  • Neuroblastoma
  • neuroblastoma
  • imaging
  • 124I-MIBG
  • 131I-MIBG
  • PET/CT
  • Neuroblastoma



University of California, San Francisco San Francisco, California  94143